Cargando…

Iatrogenic pseudoaneurysm after bevacizumab therapy in patients with metastatic colorectal cancer: Two case reports

Pseudoaneurysms are extremely rare in patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI and bevacizumab in the first-line setting. We herein present two rare cases of iatrogenic pseudoaneurysm developing in patients with mCRC after administration of FOLFIRI and bevacizumab. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ching-Chun, Tsai, Hsiang-Lin, Huang, Ching-Wen, Yeh, Yung-Sung, Tsai, Tzu-Hsueh, Wang, Jaw-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174392/ https://www.ncbi.nlm.nih.gov/pubmed/30345042 http://dx.doi.org/10.3892/mco.2018.1712

Ejemplares similares

An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness
por: Tsai, Hsiang-Lin, et al.
Publicado: (2019)

Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()
por: Lu, Chien-Yu, et al.
Publicado: (2015)

A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab
por: Chang, Tsung-Kun, et al.
Publicado: (2021)

Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Effectiveness and Cost-Utility Analysis of Different Doses of Irinotecan Plus Bevacizumab in Patients With Metastatic Colorectal Cancer: A Long-Term and Prospective Cohort Study
por: Shi, Hon-Yi, et al.
Publicado: (2022)

Effects of the number of neoadjuvant therapy cycles on clinical outcomes, safety, and survival in patients with metastatic colorectal cancer undergoing metastasectomy
por: YEH, YUNG-SUNG, et al.
Publicado: (2023)

Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2016)

UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI
por: Hsieh, Yi-Chien, et al.
Publicado: (2021)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

MicroRNA-148a induces apoptosis and prevents angiogenesis with bevacizumab in colon cancer through direct inhibition of ROCK1/c-Met via HIF-1α under hypoxia
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol
por: Chen, Shang-Hung, et al.
Publicado: (2019)

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer
por: Ma, Cheng-Jen, et al.
Publicado: (2017)

Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial †
por: Tsai, Hsiang-Lin, et al.
Publicado: (2017)

Clinicopathological Features and Oncological Outcomes of Early and Late Recurrence in Stage III Colorectal Cancer Patients after Adjuvant Oxaliplatin-Based Therapy
por: Chang, Yu-Tang, et al.
Publicado: (2023)

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial
por: Ma, Cheng-Jen, et al.
Publicado: (2019)

EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function
por: Huang, Ching-Wen, et al.
Publicado: (2017)

First-decade patient with colorectal cancer carrying both germline and somatic mutations in APC gene
por: Yeh, Yung-Sung, et al.
Publicado: (2017)

Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series
por: Tsai, Hsiang-Lin, et al.
Publicado: (2022)

Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer
por: Yeh, Yung-Sung, et al.
Publicado: (2020)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
por: Yeh, Yung-Sung, et al.
Publicado: (2014)

Clinical Outcomes of Patients with Peritoneal Metastasis-Only Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI Through Irinotecan Dose Escalation According to UGT1A1 Polymorphism: Compared to Liver Metastasis-Only, and Lung Metastasis-Only
por: Li, Ching-Chun, et al.
Publicado: (2022)

Comparison of Next-Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment-Related Genomic Status in Patients with Metastatic Colorectal Cancer
por: Su, Wei-Chih, et al.
Publicado: (2022)

A Prospective Study of Comparing Multi-Gene Biomarker Chip and Serum Carcinoembryonic Antigen in the Postoperative Surveillance for Patients with Stage I-III Colorectal Cancer
por: Chang, Yu-Tang, et al.
Publicado: (2016)

miR‐148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF‐1α under non‐hypoxia/hypoxia conditions
por: Tsai, Hsiang‐Lin, et al.
Publicado: (2019)

Role of non-coding RNAs in radiosensitivity of colorectal cancer: A narrative review
por: Huang, Chun-Ming, et al.
Publicado: (2022)

Robotic colorectal surgery for laparoscopic surgeons with limited experience: preliminary experiences for 40 consecutive cases at a single medical center
por: Huang, Ching-Wen, et al.
Publicado: (2015)

Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis
por: Chen, Yen-Cheng, et al.
Publicado: (2023)

MicroRNAs as Predictive Biomarkers in Patients with Colorectal Cancer Receiving Chemotherapy or Chemoradiotherapy: A Narrative Literature Review
por: Yang, I-Ping, et al.
Publicado: (2023)

Dose-Dependent Relationship Between Metformin and Colorectal Cancer Occurrence Among Patients with Type 2 Diabetes—A Nationwide Cohort Study()()()
por: Chang, Yu-Tang, et al.
Publicado: (2018)

The impact on clinical outcome of high prevalence of diabetes mellitus in Taiwanese patients with colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2012)

Efficacy of concurrent radiotherapy in patients with locally advanced rectal cancer and synchronous metastasis receiving systemic therapy
por: Yin, Tzu-Chieh, et al.
Publicado: (2023)

TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer
por: Hsu, Hung-Chih, et al.
Publicado: (2019)

Embolization of iatrogenic uterine pseudoaneurysm
por: Boi, Luca, et al.
Publicado: (2017)

Iatrogenic femoral vein pseudoaneurysm
por: Isoda, Ryutaro, et al.
Publicado: (2020)

Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
por: Yeh, Yung-Sung, et al.
Publicado: (2017)

Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer
por: Huang, Ching-Wen, et al.
Publicado: (2021)

Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer
por: Huang, Ching-Wen, et al.
Publicado: (2015)

PTPRT and PTPRD Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Two rare cases of synchronous and metachronous colonic metastases in patients with advanced gastric cancer
por: Su, Wei-Chih, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nvs9ig9vj7g5m2cjh3im8q3ufj